id,filing_uuid,filing_type,registrant_name,registrant_id,client_name,filing_year,filing_period,issue_code,specific_issues,government_entities,income_amount,expense_amount,is_no_activity,is_termination,received_date
1844617,1fdfbfcf-bb2e-43dd-abd9-aa5b2811ce32,Q2,COVINGTON & BURLING LLP,11195,"FABRE-KRAMER PHARMACEUTICALS, INC",2016,second_quarter,PHA,Policy regarding demonstration of effectiveness for new drug approvals.,"HOUSE OF REPRESENTATIVES,SENATE",,,0,0,2016-07-15T19:14:22.717000-04:00